--- title: "Weekly Recap | Elevance Health +6.8%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/301466602.md" description: "Elevance Health rose 6.8% this week to close at $412.70, while the S&P 500 gained 1.15%, leaving the shares roughly 5.65 percentage points ahead of the benchmark. The move was not a straight line: Monday opened near $387.67 and dipped to $385.00 before recovering, Tuesday and Wednesday pushed higher, Thursday cooled back to $400.94, and Friday jumped to a session high of $418.56 before settling at $412.70. Friday volume of about 2.1m shares was well above the earlier daily range of 0." datetime: "2026-10-10T06:32:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301466602.md) - [en](https://longbridge.com/en/news/301466602.md) - [zh-HK](https://longbridge.com/zh-HK/news/301466602.md) generator: "portal-rs" --- # Weekly Recap | Elevance Health +6.8%, most brokers rate it buy ## The Week Elevance Health rose 6.8% this week to close at $412.70, while the S&P 500 gained 1.15%, leaving the shares roughly 5.65 percentage points ahead of the benchmark. The move was not a straight line: Monday opened near $387.67 and dipped to $385.00 before recovering, Tuesday and Wednesday pushed higher, Thursday cooled back to $400.94, and Friday jumped to a session high of $418.56 before settling at $412.70. Friday volume of about 2.1m shares was well above the earlier daily range of 0.7m to 1.2m, making it the most active session of the week. ## Key Events The main company item was the announcement that third-quarter fiscal 2026 results will be released before the open on 21 October, followed by a conference call and webcast. That schedule put the managed-care group back in focus. On Monday, Elevance Health’s consensus price target was raised 21.82% in Mexican peso terms, though this appears to be an aggregation and currency-conversion shift rather than a fresh rating action from a single broker. On 9 October the stock outperformed peers in a strong trading session, while a media piece raised questions about whether insiders breached their fiduciary duties to shareholders, a governance discussion without a settled conclusion. There were no material company filings this week. ## Analyst Ratings Coverage stands at 22 institutions: 12 say buy, 3 say outperform, 7 say hold, and there are no underperform or sell ratings, with no no-opinion calls. The consensus rating is buy, and the consensus target price of $451.48 sits about 9.4% above the current $412.70. Targets range from $393.00 to $492.00, a spread of about $99 that shows some disagreement on how much upside remains. Within the managed-care industry, Elevance ranks 3rd in analyst ratings among 9 peers. ## The Week Ahead US macro starts early: NFIB small-business sentiment and existing-home sales arrive on 13 October, followed by CPI and core CPI on 14 October, where the forecast for core CPI is a small step up from 2.4% to 2.5% year over year. Price pressures feed directly into assumptions about medical-cost trends and margins across the sector. The bigger stock-specific catalyst is the third-quarter release on 21 October before the open, with consensus looking for EPS around $4.22 and revenue near $49.2bn. Management’s comments on the medical loss ratio and membership count will shape the next leg. ## In Short The stock finished the week up 6.8%, ahead of the S&P 500 by roughly 5.65 percentage points, and now trades near the top of its 60-day range, just below the $427.17 intraday high from 14 September. Valuation at roughly 18x earnings and 1.99x book is not cheap or stretched for a managed-care name, while the rating complex leans favourable: 22 analysts, a buy consensus, and a target about 9.4% above spot. The latest session’s large-lot flow, however, showed more selling than buying, a short-term split signal. The next test is whether the 21 October earnings confirm medical-cost control and revenue growth, and whether inflation prints shift the broader sector’s risk appetite. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ELV.US](https://longbridge.com/en/quote/ELV.US.md) ## Related News & Research - [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md) - [Elevance Health, Inc. $ELV Stock Position Cut by Vontobel Holding Ltd.](https://longbridge.com/en/news/302257360.md) - [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md) - [Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion](https://longbridge.com/en/news/302542349.md) - [ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%](https://longbridge.com/en/news/302542475.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**